2,4,6-triiodophenol acts as a small-molecule inhibitor of human myosin-6, reducing its interaction with F-actin and decreasing vesicle fusion events.
Answers are grounded in this paper and cite their sources.
Does not support clinical translation; leaves open myosin-6 inhibition as a research tool pending mammalian validation.
Myosin-6 is an actin-based motor protein that moves its cargo towards the minus-end of actin filaments. Mutations in the gene encoding the myosin-6 heavy chain and changes in the cellular abundance of the protein have been linked to hypertrophic cardiomyopathy, neurodegenerative diseases, and cancer. Here, we present a detailed kinetic characterization of the human myosin-6 motor domain, describe the effect of 2,4,6-triiodophenol on the interaction of myosin-6 with F-actin and nucleotides, and show how addition of the drug reduces the number of myosin-6-dependent vesicle fusion events at the plasma membrane during constitutive secretion.
No takes yet. Share an insight, caveat, or question.
Heissler et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: